Dithiothreitol treatment of red blood cells

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

72
Reader(s)
176
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 33 , ISSUE 4 (Oct 2017) > List of articles

Dithiothreitol treatment of red blood cells

C.B. Bub

Keywords : dithiothreitol (DTT), indirect antiglobulin test, Kell system, daratumumab

Citation Information : Immunohematology. Volume 33, Issue 4, Pages 170-172, DOI: https://doi.org/10.21307/immunohematology-2019-025

License : (Transfer of Copyright)

Published Online: 16-October-2019

ARTICLE

ABSTRACT

Dithiothreitol (DTT), a reducing reagent, has multiple applications in blood bank testing. DTT disrupts the bridging of the disulfide bonds between amino acid residues necessary for structural conformation of some proteins and the bonds holding an IgM molecule in the pentameric formation. DTT treatment of red blood cells (RBCs) can denature or modify certain blood group antigens—in particular, those in the Kell, Lutheran, YT, JMH, LW, Cromer, Indian, Dombrock, and Knops systems—and prevent recognition by the corresponding antibodies. It also destroys RBC CD38, allowing DTT-treated RBCs to be used to avoid testing interference by therapeutic anti-CD38 preparations. DTT treatment can be used to disperse spontaneous agglutination of RBCs caused by heavy IgM autoantibody coating that invalidates ABO/Rh cell grouping and direct antiglobulin tests.

Graphical ABSTRACT

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share